Trial Profile
A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Biogen
- 31 Mar 2022 This trial has been completed in Czech Republic as reported by European Clinical Trials Database record.
- 16 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Nov 2008 New trial record.